Compare Repligen Corporation Common Stock (RGEN) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Tesla, Inc. — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Tesla, Inc. trades at $362.37 (market cap $1.48T). The key difference: Tesla, Inc. is far larger — about 132.9× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Tesla, Inc. for 88 Days on average.
| RGEN | TSLA | |
|---|---|---|
Market Cap | $11.14B | $1.48T |
Volume | 1,259,263 | 18,314,332 |
Sector | Health | Consumer Cyclical |
52-Week High | $194.57 | $489.88 |
52-Week Low | $102.87 | $298.16 |
Typical Hold Time | 0 Days | 88 Days |
Enterprise Value | $11.02B | $1.45T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Tesla (TSLA) trades at $367.16, down 2.88% on the day, amid mixed signals. The technical outlook is bullish based on moving averages, but oscillators are neutral. Recent earnings showed a Q2 2026 miss after two prior beats. Revenue declined slightly in 2025 to $94.83B, with net income margin compressing to 4%. The company maintains a strong balance sheet with $36.56B in cash, though valuation ratios like a P/E of 347.44 remain elevated. News highlights focus on autonomous driving approvals in Europe and a potential cheaper EV model.
Tesla's investment case balances high growth expectations in autonomy and energy against near-term execution risks and rich valuations. The consensus price target of $441.36 implies upside, but investors face risks from competitive pressures, volatile earnings, and the stock's sensitivity to sentiment shifts around its AI and robotics initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
